X. Fabregat

发表

Her-2/neu Expression in Prostate Cancer

J. Lloreta, M. Salido, J. Carles, 2004, Clinical Cancer Research.

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

J. Carles, M. Climent, J. Albanell, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

J. Carles, J. Albanell, I. Tusquets, 2006 .

Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis.

V. Moreno, I. Bover, X. Fabregat, 1998, European journal of cancer.

Decreased survival of patients with lung cancer admitted to a teaching hospital through the emergency department in Barcelona, Spain.

N. Malats, M. Porta, F. Macià, 1998, Journal of epidemiology and community health.

215 Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial

J. Carles, I. Tusquets, R. Ibeas, 1997 .

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

J. Carles, J. Tabernero, Á. Arcusa, 1998, Acta oncologica.

Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

J. Carles, M. Climent, E. Esteban, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.

Meritxell Bellet, Francesc Solé, S. Serrano, 2006, Cancer genetics and cytogenetics.

Intratumoral heterogeneity of HER2/neu and topoisomerase IIalpha in breast cancer: a case with clonal monosomy 17.

S. Serrano, F. Solé, M. Salido, 2004, Cancer genetics and cytogenetics.

Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid.

S. Serrano, J. Lloreta, X. Fabregat, 1994, Ultrastructural pathology.

Absence of CHEK2 mutations in Spanish families with hereditary breast cancer.

A. Pérez-Lezaun, S. Serrano, F. Solé, 2005, Cancer genetics and cytogenetics.

Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer.

J. Carles, J. Albanell, A. Navarro, 2006, International journal of radiation oncology, biology, physics.

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

S. Serrano, F. Solé, M. Salido, 2005, Breast Cancer Research.

Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.

E. Campo, S. Serrano, J. Albanell, 2006, Endocrine-related cancer.

Characterization of HER1 (c-erbB1) Status in Locally Advanced Breast Cancer Using Fluorescence in situ Hybridization and Immunohistochemistry

S. Serrano, F. Solé, M. Salido, 2005, Tumor Biology.

Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

E. Campo, S. Serrano, J. Albanell, 2006 .

Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage

N. Malats, A. Carrato, F. Real, 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Vegetable and fruit intake and the risk of lung cancer in women in Barcelona, Spain.

N. Malats, A. Agudo, C. Pallarés, 1997, European journal of cancer.

Activation of nuclear factor- j B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

E. Campo, S. Serrano, J. Albanell, 2006 .

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

J. Carles, E. Gallardo, J. Gayo, 2010, International journal of radiation oncology, biology, physics.

A comparative study of HER2/neu amplification and overexpression using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients

S. Serrano, F. Solé, M. Salido, 2002, Revista de Oncología.

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.

J. Carles, J. Albanell, I. Tusquets, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Expression of cyclooxygenase-2 mRNA (COX2-mRNA) in peripheral blood (PB) of head and neck cancer patients (HNC) and healthy controls (HC).

R. Artells, X. Fabregat, M. Amat, 2004, Journal of Clinical Oncology.

Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage

N. Malats, A. Carrato, F. Real, 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Lung cancer and cigarette smoking in women: A case‐control study in barcelona (Spain)

A. Agudo, A. Barnadas, J. Planas, 1994, International journal of cancer.